JP2020504628A5 - - Google Patents

Download PDF

Info

Publication number
JP2020504628A5
JP2020504628A5 JP2019556411A JP2019556411A JP2020504628A5 JP 2020504628 A5 JP2020504628 A5 JP 2020504628A5 JP 2019556411 A JP2019556411 A JP 2019556411A JP 2019556411 A JP2019556411 A JP 2019556411A JP 2020504628 A5 JP2020504628 A5 JP 2020504628A5
Authority
JP
Japan
Prior art keywords
sequence
amino acid
chain
cancer
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019556411A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020504628A (ja
JP7221213B2 (ja
Filing date
Publication date
Priority claimed from CN201611246592.0A external-priority patent/CN108250302A/zh
Application filed filed Critical
Publication of JP2020504628A publication Critical patent/JP2020504628A/ja
Publication of JP2020504628A5 publication Critical patent/JP2020504628A5/ja
Application granted granted Critical
Publication of JP7221213B2 publication Critical patent/JP7221213B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019556411A 2016-12-29 2017-12-27 多官能性タンパク質 Active JP7221213B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201611246592.0A CN108250302A (zh) 2016-12-29 2016-12-29 一种多功能蛋白质
CN201611246592.0 2016-12-29
PCT/CN2017/118984 WO2018121605A1 (zh) 2016-12-29 2017-12-27 一种多功能蛋白质

Publications (3)

Publication Number Publication Date
JP2020504628A JP2020504628A (ja) 2020-02-13
JP2020504628A5 true JP2020504628A5 (enExample) 2021-07-26
JP7221213B2 JP7221213B2 (ja) 2023-02-13

Family

ID=62710858

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019556411A Active JP7221213B2 (ja) 2016-12-29 2017-12-27 多官能性タンパク質

Country Status (5)

Country Link
US (1) US11530264B2 (enExample)
EP (1) EP3578570A4 (enExample)
JP (1) JP7221213B2 (enExample)
CN (2) CN108250302A (enExample)
WO (1) WO2018121605A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2959480T3 (es) 2014-02-07 2024-02-26 Univ Mcmaster Acoplador de células T - antígeno trifuncional y métodos y usos del mismo
EP3694997A4 (en) 2017-10-12 2021-06-30 Mcmaster University T cell-antigen coupler with y182t mutation and methods and uses thereof
US10640562B2 (en) * 2018-07-17 2020-05-05 Mcmaster University T cell-antigen coupler with various construct optimizations
CN112689642B (zh) * 2018-07-17 2025-01-17 特拉姆维拉免疫美国有限公司 具有各种不同的构建物优化的t细胞抗原偶联物
US11110123B2 (en) 2018-07-17 2021-09-07 Triumvira Immunologics Usa, Inc. T cell-antigen coupler with various construct optimizations
CN110862967A (zh) * 2018-08-27 2020-03-06 天津天锐生物科技有限公司 一种不依赖细胞因子培养的自然杀伤细胞系silk-nk
WO2020081786A1 (en) * 2018-10-17 2020-04-23 Immunome, Inc. Exosome-targeting bispecific antibodies
WO2020165374A1 (en) * 2019-02-14 2020-08-20 Ose Immunotherapeutics Bifunctional molecule comprising il-15ra
CN113166273A (zh) * 2019-07-25 2021-07-23 天境生物科技(上海)有限公司 具有il-7活性的双功能分子
CN113321738A (zh) * 2020-02-27 2021-08-31 启愈生物技术(上海)有限公司 肿瘤靶向、抗cd3和t细胞激活三功能融合蛋白及其应用
CN112110988A (zh) * 2020-08-21 2020-12-22 温州医科大学 一种具有毛发生长作用的多肽类似物及制备方法和应用
AU2022283819A1 (en) 2021-06-01 2024-01-04 Triumvira Immunologics Usa, Inc. Claudin 18.2 t cell-antigen couplers and uses thereof
US11453723B1 (en) 2021-06-25 2022-09-27 Mcmaster University BCMA T cell-antigen couplers and uses thereof
CN116102655B (zh) * 2021-08-19 2026-08-04 南京吉盛澳玛生物医药有限公司 靶向pd-l1/pd-1的抗体及其应用
WO2023036270A1 (zh) * 2021-09-09 2023-03-16 启愈生物技术(上海)有限公司 抗原靶向、抗cd16a和免疫效应细胞激活三功能融合蛋白及其应用
CN122094976A (zh) * 2023-10-31 2026-05-26 免疫生物公司 多链嵌合多肽和其用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5986059A (en) * 1996-06-14 1999-11-16 Bayer Corporation T-cell selective interleukin-4 agonists
AU2001270609A1 (en) * 2000-06-30 2002-01-14 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Heterodimeric fusion proteins
MX2007013875A (es) * 2005-05-11 2008-01-28 Philogen Spa Proteinas de fusion del anticuerpo l19 contra fibronectina ed-b e interlucina 12.
EP2388266B1 (en) 2007-05-11 2014-04-23 Altor BioScience Corporation Fusion molecules and IL-15 variants
CN101830986A (zh) * 2009-03-13 2010-09-15 北京表源生物技术有限公司 一种融合蛋白多聚体
CN101550191B (zh) * 2009-05-15 2011-08-24 无锡胜博生物技术有限公司 一种恶性黑素瘤t细胞纳米抗体、其编码序列及应用
RU2583876C2 (ru) * 2009-08-17 2016-05-10 Роше Гликарт Аг Иммуноконъюгаты направленного действия
JP6251570B2 (ja) * 2010-09-21 2017-12-20 アルター・バイオサイエンス・コーポレーション 多量体il−15可溶性融合分子並びにその製造及び使用方法
WO2012143524A2 (en) 2011-04-20 2012-10-26 Genmab A/S Bispecific antibodies against her2 and cd3
CN102559696A (zh) * 2011-09-26 2012-07-11 无锡赛特基因生物科技有限公司 一种重组人白细胞介素-15的高效可溶性表达方法
CN202239821U (zh) 2011-09-27 2012-05-30 上海宏功机械科技有限公司 偏心强力反刮锪组合刀具
PL3489254T3 (pl) * 2012-04-30 2023-01-30 Biocon Limited Ukierunkowujące/immunomodulujące białko fuzyjne i sposoby jego otrzymywania
US9682143B2 (en) * 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
US20160145348A1 (en) * 2013-03-14 2016-05-26 Fred Hutchinson Cancer Research Center Compositions and methods to modify cells for therapeutic objectives
EP3093295B1 (en) * 2014-01-08 2020-05-27 Shanghai Hengrui Pharmaceutical Co., Ltd. Il-15 heterogeneous dimer protein and uses thereof

Similar Documents

Publication Publication Date Title
JP2020515282A5 (enExample)
JP2020508663A5 (enExample)
Chen et al. Efficacy, safety, and challenges of CAR T-cells in the treatment of solid tumors
JP7267321B2 (ja) 改善された特異性を有する改変型tリンパ球
US11530264B2 (en) Multifunctional protein
EP3575325A1 (en) Multi-target chimeric antigen receptor
US10982189B2 (en) Methods of improving vector transduction efficiency into T lymphocytes
JP2022515194A5 (enExample)
CA2907397C (en) Modified t lymphocytes
CN105418765B (zh) Cd19靶向性的嵌合抗原受体和nkt细胞及其制法和应用
EP3828267A2 (en) Car-t lymphocytes engineered to home to lymph node b cell zone, skin, or gastrointestinal tract
FI3348571T3 (fi) Yksidomeeninen vasta-aine ohjelmoitu solukuolema -ligandille (pd-l1) ja siitä peräisin oleva proteiini
CN113396215A (zh) 表达嵌合抗原受体(car)的骨髓浸润淋巴细胞(mil)、其制造方法及在疗法中使用的方法
AU2013204923A1 (en) Modified t lymphocytes having improved specificity
Long et al. HLA-class II restricted TCR targeting human papillomavirus type 18 E7 induces solid tumor remission in mice
AU2017204617B2 (en) Chimeric antigen receptors
CN106478823B (zh) Her1靶向性的嵌合抗原受体和nkt细胞及其制法和应用
Atherton et al. Abstract B096: Oncolytic vaccination for HPV induced cancer
Gibson et al. Electrovaccination of domestic cats with a hybrid heterologous Her2 DNA vaccine overcomes immune tolerance to self Her2.
HK1234782B (en) Methods of improving vector transduction efficiency into t lymphocytes
NZ712373B2 (en) Modified t lymphocytes
HK1218049B (en) Modified t lymphocytes having improved specificity